October 27, 2015. The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) organized a gathering of US and European experts to conduct a rigorous examination of potential issues surrounding sodium-glucose cotransporter-2 (SGLT2) inhibitors and their possible relationship to diabetic ketoacidosis (DKA). Upon review of the available material and following a thorough discussion of the impact of SGLT2 inhibitors on human metabolism, the experts concluded that the prevalence of DKA is infrequent and the risk-benefit ratio favors the continued use of SGLT2 inhibitors with no changes in current recommendations. The AACE and ACE also called upon pharmaceutical companies to continue to investigate the mechanisms behind the metabolic effect of SGLT2 inhibitors. They noted that the diagnosis of DKA is often missed or delayed due to atypical presentation involving lower-than-anticipated glucose levels or other misleading laboratory values. You can click here to download a summary of the conference’s conclusions, or follow this link to read the conference press release.